Bionomics Limited Stock Current Valuation
| BNOEFDelisted Stock | USD 0.01 0.00 0.00% |
Valuation analysis of Bionomics Limited helps investors to measure Bionomics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Bionomics' price fluctuation is very steady at this time. Calculation of the real value of Bionomics Limited is based on 3 months time horizon. Increasing Bionomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bionomics pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Bionomics Limited. Since Bionomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bionomics Pink Sheet. However, Bionomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0131 | Real 0.0124 | Hype 0.0131 | Naive 0.0172 |
The real value of Bionomics Pink Sheet, also known as its intrinsic value, is the underlying worth of Bionomics Limited Company, which is reflected in its stock price. It is based on Bionomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bionomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bionomics Limited helps investors to forecast how Bionomics pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bionomics more accurately as focusing exclusively on Bionomics' fundamentals will not take into account other important factors: Bionomics Limited Company Current Valuation Analysis
Bionomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bionomics Current Valuation | 27.83 M |
Most of Bionomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionomics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Bionomics Limited has a Current Valuation of 27.83 M. This is 99.81% lower than that of the Healthcare sector and 99.4% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.83% higher than that of the company.
Bionomics Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bionomics could also be used in its relative valuation, which is a method of valuing Bionomics by comparing valuation metrics of similar companies.Bionomics is currently under evaluation in current valuation category among its peers.
Bionomics Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 27.83 M | |||
| Shares Outstanding | 1.35 B | |||
| Shares Owned By Insiders | 6.00 % | |||
| Shares Owned By Institutions | 48.96 % | |||
| Price To Earning | (34.09) X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 8.29 X | |||
| Revenue | 263.63 K | |||
| Gross Profit | (9.94 M) | |||
| EBITDA | (21.92 M) | |||
| Net Income | (21.76 M) | |||
| Cash And Equivalents | 33.56 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 693.62 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 12.46 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (21.76 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 22 | |||
| Beta | 2.18 | |||
| Market Capitalization | 29.11 M | |||
| Total Asset | 65.31 M | |||
| Retained Earnings | (103 M) | |||
| Working Capital | 47 M | |||
| Current Asset | 58 M | |||
| Current Liabilities | 11 M | |||
| Z Score | 23.2 | |||
| Net Asset | 65.31 M |
About Bionomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bionomics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionomics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Bionomics Pink Sheet
If you are still planning to invest in Bionomics Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bionomics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |